Key Facts

PIPS Key Facts
Active Substance
Active Substance:
  • cosibelimab
Invented Name
Not yet available
PIP Number MHRA-100152-PIP01-21
Pharmaceutical form(s)
  • All forms
  • All forms
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of cutaneous squamous cell carcinoma
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

PIPS Decision Documents
Decision Document Decision Document on a Paediatric Investigation Plan (PIP):cosibelimab.pdf
Published Date 03/12/2021